Funding for this research was provided by:
European Research Council (682345)
Program "Investissements d'avenir" (ANR-10-IAIHU-06, ANR-18-RHUS-005)
Health Research and Development (ZonMw) and Epilepsiefonds
Suh Kyungbae Foundation
National Research Foundation of Korea (NRF) grant funded by the Korea government, Ministry of Science and ICT (2019R1A3B2066619)
Received: 15 November 2020
Accepted: 18 November 2020
First Online: 6 January 2021
Availability of data and materials
: All data generated or analyzed during this study are included in this published article (and its supplementary information files).
: These studies received approval by the ethical committee CPP Ile de France II (No. ID-RCB/EUDRACT-2015-A00671-48), the Severance Hospital and KAIST Institutional Review Board and Committee on Human Research, and Amsterdam UMC (W13_85;W15_262).
: Informed consent to participate in this study were obtained from all participants (or their parent or legal guardian in the case of children).
: JH.L is a co-founder and CTO of SoVarGen, Inc., which seeks to develop new diagnostics and therapeutics for brain disorders.